Frazier Life Sciences Management as of Sept. 30, 2023
Portfolio Holdings for Frazier Life Sciences Management
Frazier Life Sciences Management holds 51 positions in its portfolio as reported in the September 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Mirum Pharmaceuticals (MIRM) | 13.5 | $205M | 6.5M | 31.60 | |
| Hillevax (HLVX) | 8.7 | $132M | 9.8M | 13.45 | |
| Krystal Biotech (KRYS) | 7.6 | $115M | 989k | 116.00 | |
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 7.4 | $112M | 12M | 9.25 | |
| Phathom Pharmaceuticals (PHAT) | 6.9 | $105M | 10M | 10.37 | |
| Bridgebio Pharma (BBIO) | 4.8 | $72M | 2.7M | 26.37 | |
| Vaxcyte (PCVX) | 3.9 | $59M | 1.2M | 50.98 | |
| Rhythm Pharmaceuticals (RYTM) | 3.6 | $54M | 2.4M | 22.93 | |
| Verona Pharma Sponsored Ads (VRNA) | 3.2 | $49M | 3.0M | 16.30 | |
| Crinetics Pharmaceuticals In (CRNX) | 3.1 | $47M | 1.6M | 29.74 | |
| Arcutis Biotherapeutics (ARQT) | 3.0 | $46M | 8.7M | 5.31 | |
| Alpine Immune Sciences (ALPN) | 2.3 | $34M | 3.0M | 11.45 | |
| Tarsus Pharmaceuticals (TARS) | 2.1 | $32M | 1.8M | 17.77 | |
| Kalvista Pharmaceuticals (KALV) | 2.1 | $31M | 3.2M | 9.63 | |
| Disc Medicine (IRON) | 2.0 | $31M | 655k | 46.98 | |
| Rocket Pharmaceuticals (RCKT) | 1.9 | $29M | 1.4M | 20.49 | |
| Revolution Medicines (RVMD) | 1.8 | $28M | 998k | 27.68 | |
| Apellis Pharmaceuticals (APLS) | 1.5 | $23M | 614k | 38.04 | |
| An2 Therapeutics (ANTX) | 1.5 | $22M | 1.4M | 16.08 | |
| Merus N V (MRUS) | 1.2 | $18M | 747k | 23.58 | |
| Syndax Pharmaceuticals (SNDX) | 1.2 | $17M | 1.2M | 14.52 | |
| Aerovate Therapeutics (AVTE) | 1.1 | $16M | 1.2M | 13.57 | |
| Anaptysbio Inc Common (ANAB) | 1.1 | $16M | 900k | 17.96 | |
| Savara (SVRA) | 1.0 | $15M | 4.0M | 3.78 | |
| Trevi Therapeutics (TRVI) | 1.0 | $15M | 6.9M | 2.18 | |
| Cogent Biosciences (COGT) | 1.0 | $15M | 1.5M | 9.75 | |
| Enliven Therapeutics (ELVN) | 0.9 | $14M | 1.1M | 13.66 | |
| Tyra Biosciences (TYRA) | 0.9 | $14M | 1.0M | 13.77 | |
| Soleno Therapeutics (SLNO) | 0.9 | $14M | 465k | 29.51 | |
| ACADIA Pharmaceuticals (ACAD) | 0.9 | $13M | 631k | 20.84 | |
| Oric Pharmaceuticals (ORIC) | 0.9 | $13M | 2.1M | 6.05 | |
| Autolus Therapeutics Spon Ads (AUTL) | 0.6 | $8.7M | 3.7M | 2.33 | |
| Silence Therapeutics Ads (SLN) | 0.6 | $8.7M | 881k | 9.83 | |
| Cerevel Therapeutics Hldng I (CERE) | 0.6 | $8.6M | 393k | 21.83 | |
| Apogee Therapeutics (APGE) | 0.6 | $8.5M | 400k | 21.30 | |
| Macrogenics (MGNX) | 0.6 | $8.4M | 1.8M | 4.66 | |
| Agios Pharmaceuticals (AGIO) | 0.5 | $7.2M | 292k | 24.75 | |
| Replimune Group (REPL) | 0.4 | $6.6M | 387k | 17.11 | |
| Intellia Therapeutics (NTLA) | 0.4 | $6.4M | 204k | 31.62 | |
| Prothena Corp SHS (PRTA) | 0.4 | $6.2M | 128k | 48.25 | |
| Theseus Pharmaceuticals | 0.4 | $6.0M | 2.2M | 2.69 | |
| Arvinas Ord (ARVN) | 0.4 | $5.6M | 285k | 19.64 | |
| Bluebird Bio (BLUE) | 0.3 | $5.2M | 1.7M | 3.04 | |
| Edgewise Therapeutics (EWTX) | 0.3 | $4.9M | 849k | 5.73 | |
| Deciphera Pharmaceuticals (DCPH) | 0.3 | $4.7M | 370k | 12.72 | |
| Sutro Biopharma (STRO) | 0.2 | $2.7M | 780k | 3.47 | |
| Gritstone Oncology Ord (GRTS) | 0.2 | $2.5M | 1.4M | 1.72 | |
| Aclaris Therapeutics (ACRS) | 0.1 | $1.8M | 264k | 6.85 | |
| Adc Therapeutics Sa SHS (ADCT) | 0.1 | $1.5M | 1.6M | 0.90 | |
| Passage Bio (PASG) | 0.1 | $1.2M | 1.8M | 0.66 | |
| Newamsterdam Pharma Company *w Exp 11/22/202 (NAMSW) | 0.1 | $951k | 500k | 1.90 |
